Who are Doxazosin extended release's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): RASi plus carvedilol, Phenylephrine bolus 50 micrograms, Midodrine + pyridostigmine, Bupivacaine-adrenaline, Bolus Phenylephrine/Ephedrine Treatment, Pseudoephedrine/Paracetamol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/doxazosin-extended-release.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Doxazosin extended release — Competitive Intelligence Brief

Doxazosin extended release (Doxazosin extended release) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic receptor antagonist. Area: Cardiovascular, Urology.

marketed Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor Cardiovascular, Urology Small molecule Live · refreshed every 30 min

Target snapshot

Doxazosin extended release (Doxazosin extended release) — University of Arkansas. Doxazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow, and also dilates blood vessels to lower blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Doxazosin extended release TARGET	Doxazosin extended release	University of Arkansas	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
RASi plus carvedilol	RASi plus carvedilol	Federal University of Minas Gerais	marketed	ACE inhibitor or ARB combined with non-selective beta-blocker	Angiotensin II receptor / ACE enzyme; beta-1 and beta-2 adrenergic receptors; alpha-1 adrenergic receptor
Phenylephrine bolus 50 micrograms	Phenylephrine bolus 50 micrograms	Rawalpindi Medical College	marketed	Alpha-1 adrenergic agonist	Alpha-1 adrenergic receptor
Midodrine + pyridostigmine	Midodrine + pyridostigmine	Seoul National University Hospital	marketed	Alpha-1 adrenergic agonist + acetylcholinesterase inhibitor combination	Alpha-1 adrenergic receptor; acetylcholinesterase
Bupivacaine-adrenaline	Bupivacaine-adrenaline	University of Aarhus	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (adrenaline component)
Bolus Phenylephrine/Ephedrine Treatment	Bolus Phenylephrine/Ephedrine Treatment	IWK Health Centre	marketed	Sympathomimetic amines / Vasopressors	Alpha-1 adrenergic receptor (phenylephrine); Alpha and beta adrenergic receptors (ephedrine)
Pseudoephedrine/Paracetamol	Pseudoephedrine/Paracetamol	McNeil AB	marketed	Decongestant/analgesic combination	Alpha-1 adrenergic receptor (pseudoephedrine); COX inhibition (paracetamol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic receptor antagonist class)

Brian J Lipworth · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 drug in this class
Hospital Authority, Hong Kong · 1 drug in this class
Japan Heart Foundation · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
San Francisco Veterans Affairs Medical Center · 1 drug in this class
Sanofi · 1 drug in this class
Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Doxazosin extended release — Competitive Intelligence Brief. https://druglandscape.com/ci/doxazosin-extended-release. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab